Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01476956 · ClinicalTrials.gov registry record
Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography
A clinical trial of Rheumatoid Arthritis, sponsored by Care Arthritis.
- Completed
- Registry status
- 571
- Enrollment target
- 20
- Study locations
NCT01476956: Completed study of Rheumatoid Arthritis, sponsored by Care Arthritis.
NCT01476956 is a study of Rheumatoid Arthritis that has completed, run by Care Arthritis. The registered enrollment target is 571 participants, below the 4,688-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01476956, a study of Rheumatoid Arthritis, has completed, sponsored by Care Arthritis.
- COMPLETED
- Registry status
- 571 participants
- Enrollment target
- 20
- Study locations
Study Summary
Recruited patients will include those about to begin Disease-Modifying Antirheumatic Drug) DMARD therapy or about to change DMARD therapy. Disease activity will be monitored systematically every 3 months by the Disease Activity Score. Changes in standard DMARD and/or anti-Tumor Necrosis Factor α (anti-TNFα) therapy will be made according to specific recommendations for patients receiving these therapies. Biomarker samples will be collected every 3 months and prior to change in DMARD and/or anti-TNF therapy as defined below. A blood sample (40 ml) for serum will be taken for biomarker studies and processed according to the international committee of Outcome Measures in Rheumatology (OMERACT) recommendations for the minimal handling of biomarker samples. A urine sample (20 ml) will also be taken and processed as for serum. Radiography (X-rays) will be conducted every 6 months (baseline, 6, 12, 18, 24 months). Patients will be followed for 2 years.
Conditions Studied
Interventions
- OTHER Observational study
Study Locations (20)
Other
- Department of Rheumatology, Copenhagen University Hospital at Glostrup - Glostrup Municipality
- Service de Rheumatologie-CHU Bordeaux Pellegrin - Bordeaux
- Le Roux Liana, Centre d'Investigation Clinique - Brest
- Centre des Consultations et imagerie de l'appareil locomoteur service de rheumatologie - Lille
- Departement de rheumatologie, Hopital Lapeyronie - Montpellier
- Rheumatologie B, Hopital Cochin - Paris
- Infirmiere de Recherche Clinique, CHU de Toulouse, Centre de Rheumatologie, Hopital Purpan - Toulouse
- Kerckhoff-Klinik, Department of Rheumatology and Clinical Immunology - Bad Nauheim
New York
- Rheumatologist Hospital for Special Surgery - New York
- Division of Rheumatology, Columbia University, College of Physicians and Surgeons - New York
- Division of Allergy, Immunology and Rheumatology, University of Rochester - Rochester
Alberta
- University of Calgary - Calgary
- Division of Rheumatology, University of Alberta Hospital - Edmonton
Maryland
- Johns Hopkins Arthritis Center, Johns Hopkins University - Baltimore
Washington
- Seattle Rheumatology Associates - Seattle
Manitoba
- Arthritis Center, University of Manitoba - Winnipeg
Newfoundland and Labrador
- Memorial University - St. John's
Ontario
- The Arthritis Research Group - Newmarket
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 571 participants |
| Start Date | 2011-10 |
| Est. Completion | 2019-12-31 |
What the finished NCT01476956 record still lists
NCT01476956 is an observational study that tracks outcomes without assigning an intervention. The registered 571 participants enrollment target is mid-sized for trials with a published cap, below the 4,688-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Observational study is the first listed.
NCT01476956 names 20 study sites across 10 states, led by Other, New York, Alberta.
Frequently Asked Questions
What is clinical trial NCT01476956 about?
NCT01476956 is a clinical study titled "Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography". Recruited patients will include those about to begin Disease-Modifying Antirheumatic Drug) DMARD therapy or about to change DMARD therapy. Disease activity will be monitored systematically every 3 months by the Disease Activity Score. Changes in standard DMARD and/or anti-Tumor Necrosis Factor α (...
What is the current status of trial NCT01476956?
This trial is currently completed. The enrollment target is 571 participants. The study started on 2011-10. Estimated completion is 2019-12-31.
What conditions does trial NCT01476956 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT01476956?
The interventions under investigation include: Observational study (OTHER).
Who is sponsoring clinical trial NCT01476956?
This trial is sponsored by Care Arthritis, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01476956 being conducted?
This trial has 20 study locations across Maryland, New York, Washington, Alberta, Manitoba. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01476956's enrollment target sits among peer trials
571 38th of 197 higher than 160 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rheumatology Diet Study
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))
RECRUITING · NA
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Physica System Total Knee Replacement Registry Study
RECRUITING · NA
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04410796 · 571 participants · Phase 2
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
- NCT05131022 · 572 participants · Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- NCT06346392 · 572 participants · Phase 3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
- NCT06615050 · 572 participants · Phase 3
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia